

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/026150 A1

(51) International Patent Classification⁷: C07D 401/12, 405/14, 401/14, A61K 31/517, A61P 35/00

(74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Sodertalje (SE).

(21) International Application Number:
PCT/GB2004/003923

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GI, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SH, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
13 September 2004 (13.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0321620.7 16 September 2003 (16.09.2003) GB
0406163.6 19 March 2004 (19.03.2004) GB

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except MG, US): ASTRAZENECA AB [SE/SI]; Sodertalje, S-151 85 (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): HENNEQUIN, Laurent, Francois, Andre [FR/FR]; AstraZeneca Pharma, Z.I. la Pompelle, BP 1050, F-51689 Reims (FR). HALSALL, Christopher, Thomas [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS



(57) Abstract: The invention concerns quinazoline derivatives of the Formula (I); wherein each of R¹, R², W, X¹, X², Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

WO 2005/026150 A1

BEST AVAILABLE COPY